Logo

Novartis' Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults

Share this

Novartis' Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults

Shots:

  • The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged <25 yrs. with B-cell acute lymphoblastic leukemia (ALL) in Sep-2018
  • The P-II JULIET results; 18mos.@ median relapse-free survival rate 64%; OR 43%; safe and effective
  • Kymriah is a CAR-T (chimeric antigen receptor T cell) therapy and has also received the US FDA approval for patients with relapsed/refractory (R/R) large B-cell lymphomas

   Ref: Nice | Image: Wikipedia


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions